{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:56:10Z","timestamp":1793822170391,"version":"4.6.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title>\n          <jats:p>Although androgen excess can manifest in many ways, the most common and recognizable symptoms are hirsutism and acne. Reports of hirsutism and acne should be taken seriously because of their possible association with medical disorders, their substantial effect on self-esteem and quality of life, and the potential for psychosocial morbidity. In patients with symptoms of androgen excess, the differential diagnosis should include physiologic hyperandrogenism of puberty, idiopathic hyperandrogenism, and polycystic ovary syndrome (PCOS). There is a great deal of overlap between the symptoms of PCOS and those of normal puberty, which makes the diagnosis of PCOS in the adolescent difficult. Treatment of acne and hirsutism should not be withheld during the ongoing longitudinal evaluation for possible PCOS. On physical examination, body mass index, blood pressure, and signs of hyperandrogenism, such as acne and hirsutism, should be evaluated. Although guidelines differ on recommended laboratory studies, most include measurement of total testosterone, free testosterone, or both, and screening for nonclassic congenital adrenal hyperplasia with a 17-hydroxyprogesterone test. Elevation of the free or total testosterone level higher than the adult female normative values is a key diagnostic feature of biochemical hyperandrogenism. Because treatment is indicated only when symptoms are distressing to the patient, the degree to which acne or hirsutism bothers the patient should be assessed. Before initiation of any medical therapy, expectations of treatment should be discussed with the patient. Anticipatory guidance is critical to help patients understand the timeline for expected responses to therapy.<\/jats:p>","DOI":"10.1097\/aog.0000000000003475","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T14:35:23Z","timestamp":1570113323000},"page":"e106-e114","source":"Crossref","is-referenced-by-count":36,"title":["Screening and Management of the Hyperandrogenic Adolescent"],"prefix":"10.1097","volume":"134","member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jogc.2017.05.022","article-title":"No. 350-hirsutism: evaluation and treatment","volume":"39","author":"Liu","year":"2017","journal-title":"J Obstet Gynaecol Can"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jpag.2007.07.004","article-title":"Adolescent female acne: etiology and management","volume":"21","author":"Olutunmbi","year":"2008","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/humupd\/dmr042","article-title":"Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society [published erratum appears in Hum Reprod Update 2013;19:207]","volume":"18","author":"Escobar-Morreale","year":"2012","journal-title":"Hum Reprod Update"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bpobgyn.2016.05.003","article-title":"Androgen excess: Investigations and management","volume":"37","author":"Lizneva","year":"2016","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3109\/09513591003686353","article-title":"Comprehensive clinical management of hirsutism","volume":"26","author":"Castelo-Branco","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ecl.2016.01.004","article-title":"Polycystic ovary syndrome in adolescents","volume":"45","author":"Witchel","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/AOG.0000000000002656","article-title":"Polycystic ovary syndrome. ACOG Practice Bulletin No. 194. American College of Obstetricians and Gynecologists","volume":"131","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"73.945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000489385","article-title":"Clitoromegaly in childhood and adolescence: behind one clinical sign, a clinical sea","volume":"12","author":"Iezzi","year":"2018","journal-title":"Sex Dev"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.fertnstert.2010.06.015","article-title":"Polycystic ovarian morphology in postmenarchal adolescents","volume":"95","author":"Codner","year":"2011","journal-title":"Fertil Steril"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jpag.2004.01.005","article-title":"Clinical and metabolic findings in adolescent females with hyperandrogenism","volume":"17","author":"Huppert","year":"2004","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1542\/peds.2015-1430","article-title":"The diagnosis of polycystic ovary syndrome in adolescents","volume":"136","author":"Rosenfield","year":"2015","journal-title":"Pediatrics"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Task Force on the Phenotype of the Polycystic Ovary Syndrome of the Androgen Excess and PCOS Society","volume":"91","author":"Azziz","year":"2009","journal-title":"Fertil Steril"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society Clinical Practice Guideline [published erratum appears in J Clin Endocrinol Metab 2019;104:39\u201340]","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1210\/jc.2018-00241","article-title":"Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society Clinical Practice Guideline","volume":"103","author":"Martin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/j.ajog.2005.02.067","article-title":"Effect of oral versus transdermal steroidal contraceptives on androgenic markers","volume":"192","author":"White","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.fertnstert.2009.05.044","article-title":"Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study","volume":"94","author":"Battaglia","year":"2010","journal-title":"Fertil Steril"},{"key":"R19-20230711","first-page":"328","article-title":"Use of spironolactone in dermatology","volume":"8","author":"Rathnayake","year":"2010","journal-title":"Skinmed"},{"key":"R20-20230711","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpag.2013.09.010","article-title":"Intermittent low-dose finasteride administration is effective for treatment of hirsutism in adolescent girls: a pilot study","volume":"27","author":"Tartagni","year":"2014","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"R21-20230711","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1097\/AOG.0000000000002297","article-title":"Obesity in adolescents. Committee Opinion No. 714. American College of Obstetricians and Gynecologists","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R22-20230711","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1210\/jc.2003-031780","article-title":"Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study [published erratum appears in J Clin Endocrinol Metab 2004;89:4655]","volume":"89","author":"Ganie","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R23-20230711","doi-asserted-by":"crossref","first-page":"e20154089","DOI":"10.1542\/peds.2015-4089","article-title":"Metformin or oral contraceptives for adolescents with polycystic ovarian syndrome: a meta-analysis","volume":"137","author":"Al Khalifah","year":"2016","journal-title":"Pediatrics"},{"key":"R24-20230711","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/humupd\/8.2.169","article-title":"Laser hair reduction in the hirsute patient: a critical assessment","volume":"8","author":"Sanchez","year":"2002","journal-title":"Hum Reprod Update"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40257-017-0316-7","article-title":"Laser and light treatments for hair reduction in Fitzpatrick skin types IV-VI: a comprehensive review of the literature","volume":"19","author":"Fayne","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"R26-20230711","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-4632.2006.03079.x","article-title":"Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Eflornithine HCl Study Group","volume":"46","author":"Wolf","year":"2007","journal-title":"Int J Dermatol"},{"issue":"suppl 3","key":"R27-20230711","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1542\/peds.2013-0490B","article-title":"Evidence-based recommendations for the diagnosis and treatment of pediatric acne. American Acne and Rosacea Society","volume":"131","author":"Eichenfield","year":"2013","journal-title":"Pediatrics"},{"key":"R28-20230711","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clindermatol.2009.03.006","article-title":"Hormonal therapy for acne: why not as first line therapy? Facts and controversies","volume":"28","author":"Katsambas","year":"2010","journal-title":"Clin Dermatol"},{"key":"R29-20230711","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ajog.2017.07.003","article-title":"Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review","volume":"218","author":"Simmons","year":"2018","journal-title":"Am J Obstet Gynecol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T20:00:18Z","timestamp":1689105618000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003475"}},"subtitle":["ACOG Committee Opinion, Number 789"],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003475","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}